PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Pfizer and Novo Nordisk have underperformed the market over the past year. Pharmaceutical giants Pfizer (NYSE: PFE) and Novo ...

Johnson & Johnson JNJ, on its second-quarter conference call, stated that it expects its oncology sales to reach $50 billion ...

You can buy shares of Healthpeak Properties and Pfizer with well less than $100 at the moment. At the moment, anyone with ...

Founded in 1998, Genmab develops customised antibodies for use in cancer treatments. Historically, the group has licensed its technology and the commercialisation of its drugs to large pharma giants ...

Some of the most high-profile acquisitions in recent years have involved women-fronted biotechs. BioSpace reviews five of the ...

Conversations with the Trump administration on its “most favored nation” policy have been productive, the executive said ...

Swiss drugmaker Roche reported better than expected first-half operating profit on Thursday, driven by strong sales of breast ...

Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...

The cancer pain market, valued at USD 6.53 billion in 2024, is projected to reach USD 11.81 billion by 2034, with a CAGR of 6 ...